Switch theme
Sign up to access all valuation multiples
Sopharma AD-Sofia is a company engaged in the production of pharmaceutical products. Its principal activities include the production and trade of medicinal substances and finished drug forms; and research and development as well as engineering and implementation activities in the field of medicinal products. It is also focused on the distribution of pharmaceuticals like medical supplies, sanitary materials, vitamins, food supplements, and cosmetics. The company's segments are the Production of pharmaceutical products; Distribution of pharmaceutical products; and Others. It generates the majority of its revenue from the Distribution of pharmaceutical products.
1933
4.7K+
Last FY Revenue $1.1B
Last FY EBITDA $107M
$906M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Sopharma achieved revenue of $1.1B and an EBITDA of $107M.
Sopharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Sopharma valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $1.1B | XXX | XXX | XXX |
| Gross Profit | XXX | $245M | XXX | XXX | XXX |
| Gross Margin | XXX | 22% | XXX | XXX | XXX |
| EBITDA | XXX | $107M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 9% | XXX | XXX | XXX |
| EBIT | XXX | $56.6M | XXX | XXX | XXX |
| EBIT Margin | XXX | 5% | XXX | XXX | XXX |
| Net Profit | XXX | $57.8M | XXX | XXX | XXX |
| Net Margin | XXX | 5% | XXX | XXX | XXX |
| Net Debt | XXX | $80.9M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of June 30, 2025, Sopharma's stock price is BGN 7 (or $4).
Sopharma has current market cap of BGN 1.2B (or $702M), and EV of BGN 1.5B (or $906M).
See Sopharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $906M | $702M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of June 30, 2025, Sopharma has market cap of $702M and EV of $906M.
Sopharma's trades at 0.8x EV/Revenue multiple, and 8.5x EV/EBITDA.
Equity research analysts estimate Sopharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Sopharma's P/E ratio is not available.
See valuation multiples for Sopharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $702M | XXX | $702M | XXX | XXX | XXX |
| EV (current) | $906M | XXX | $906M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 0.8x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 8.5x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 16.0x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | 12.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 861.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSopharma's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $40K for the same period.
Sopharma's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Sopharma's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Sopharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 9% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $40K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 2% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 17% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Ansell | XXX | XXX | XXX | XXX | XXX | XXX |
| Polymed | XXX | XXX | XXX | XXX | XXX | XXX |
| Farmaceutica Remedia | XXX | XXX | XXX | XXX | XXX | XXX |
| Etropal | XXX | XXX | XXX | XXX | XXX | XXX |
| Sopharma Trading | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sopharma acquired XXX companies to date.
Last acquisition by Sopharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Sopharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Sopharma founded? | Sopharma was founded in 1933. |
| Where is Sopharma headquartered? | Sopharma is headquartered in Bulgaria. |
| How many employees does Sopharma have? | As of today, Sopharma has 4.7K+ employees. |
| Is Sopharma publicy listed? | Yes, Sopharma is a public company listed on BUL. |
| What is the stock symbol of Sopharma? | Sopharma trades under SFA ticker. |
| When did Sopharma go public? | Sopharma went public in 2000. |
| Who are competitors of Sopharma? | Similar companies to Sopharma include e.g. Ansell, Polymed, Farmaceutica Remedia, Etropal. |
| What is the current market cap of Sopharma? | Sopharma's current market cap is $702M |
| Is Sopharma profitable? | Yes, Sopharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
